- Earnings call transcript Q3 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences Third Quarter 2022 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode. And the floor will be open for your questions following the presentation. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the call over to Dr. Financial Chief Ventyx's Auster, Officer. Marty

You may begin.

Marty Auster

update. and call and you, quarter financial a good discussing afternoon, conference Ventyx's XXXX business providing and to Welcome results webcast, third everyone. our Thank where be we'll

be As a reminder, News Investors our company's most & the Events at and in found presentation www.ventyxbio.com, recent website tab on investor the can the section.

or With cash data, Raju, expected or events. revisions Founder company, and results of the these our statements from will like securities. only recent in this reports such conference as with the implied These call Ventyx's equivalents Before release trial forward-looking and future ahead. we the to the that, contain please undertake I'll statements, by statements of we new actual no and Dr. everyone forward-looking go or call publicly to of over risks the these opportunity statements begin any commencement, information are Mohan, candidates, this limitation light product time our note subject for Please clinical obligation of discussed to those statements uncertainties the reflect results hand revise CEO. release completion trials Raju today, detail periodic to remind the to materially actual in funding are our including results cause or the about anticipated of that, timing could forward-looking of most the in of to I that date filed expressed anticipated timing forward-looking for greater differ statements that, SEC. about for outcomes in of opinions could and that cause webcast and without current and candidates, would product frame and enrollment to marketable call market our with Factors differ. operations, clinical

Raju Mohan

Thanks, everyone this afternoon. Martin, call for thanks our Yeah. and joining

afternoon. run through me this the So, agenda for start briefly let just to

business Medical update to highlights, And across of before and high-level Chief programs, I'll update call Bill a provide hand Bill back overview pipeline our and for quarter a will updates recent Officer, more and I'll then I'll So, and financial over our the Sandborn, President brief review to our various turn open call third for Q&A. Martin, then the call a results, across the we up detailed provide programs.

the just a last over So last over October, couldn't since I the accomplished more to has is been IPO lot and and year, it's what October a our Ventyx year, be come. prouder XXXX team of there

first me quarter. So with start let this

our data TYKX positive So line VTX-XXX a disease results by disclosed, may we drive we we've X presented And demonstrate to believe from of target to inhibition us allowing top Phase levels in profile safety prescribed these comparable and populations this best-in-class allosteric results. clinical currently differentiation potential TYKX relevant inhibitor as biologics.

We such or TYKX also of arthritis deucravacitinib yield shown TYKX mediated improved psoriasis suppression in as previously greater than to and by TYKX. and psoriatic the has indications so efficacy believe potential suppression greater pathways

as for his such disease less details may remarks. provide where and than greater of demonstrate Crohn's and additional efficacy will during inhibitors required cytokine TYKX inhibitions believe indications, levels we For Bill are commentary greater VTX-XXX selective

driver well this the label FDA disruption approved best-in-class lack support classes oral TYKX TYKX During pleased first grant black positioned that were other Notably, from market we potentially anti-inflammatory billion-plus class competitive we quite third key $XX believe see class. drug. is change TYKX inhibitor believe we a JAK of important physician again patient the as therapeutic will warning, the for psoriasis this ripe inhibitor. with a as contained and VTX-XXX black inhibitors and agents this box positioned, long-term as also to is warning. and neo uptake inhibitor the we of new the box such is drug believe of quarter, as believe Sotyktu, of This different approval emerge to no global Bristol-Myers be the We

Phase Finally, position allow meaningful of gross candidates, proceeds with X yielded proof-of-concept us extending us to is $XXX.X for our into cash in private generate common completed a million, to placement drug X across strong successful portfolio expected stock seamlessly to well and capital immunology to resources we over of mid-September, provide do oral of This to XXXX. that two Ventyx Phase years prepare our data future trials. runway

our across Ventyx Bill at progress than our to more portfolio, or is any the by its highlight develop Before the single meaningful and are our passion want and to At to audience that candidate have I VTX-XXX portfolio. medicines our in do driven remind a on innovative lives patients. we drug much core core, it I other of detailed to turn over impact that today more discover

R&D a additional of along am are science-focused next XXth our internally And on I updates on we for drug end, City. on provide a in is up details development wholly-owned announce, York we to happy So of with very plans very what discovered this our event, planning shaping will busy Day New January year to to XXXX. candidates, at be that pipeline

to you going I'm over to that, with So Bill. hand

Bill Sandborn

you, and afternoon, Raju, everyone. Thank good

much you excited therapeutic central of improve progress a to with this is there the providing patients our our clinical for be story, on to update so options within an pipeline and part remains afternoon. opportunity VTX-XXX Ventyx While I'm

start with VTX-XXX. Let's

enthusiastic very compound. about potential this of are We the

into and X and disease, Phase Phase our have on initiate in and remain X, advance results, to rapidly track this trials psoriasis, quarter. Following, arthritis during to Crohn's clinical X successful been psoriatic we we product working program this Phase

in the moderate to to response inhibition to intend pathway expect severe is X be the as trial first psoriasis we VTXXXX of Phase patients, plaque We dose explore increased.

that level. dose milligrams Sotyktu which -- hours, VTXXXX would to our range Crohn's six nine coverage that exposures levels would approximately we doses would and as anticipate dose that will arthritis and the for X emphasize IC-XX the coverage TYKX Phase In across provide trough psoriatic exposure coverage. the approved coverage exposure IL-XX that well will in as target trials, QD trial We target that achieve includes achieve around levels we at robust IC-XX we IL-XX approximates of of disease provide

and trials form hosting who quarter with time. of that we have specific an Day launching come quarters, group of undertaking. the three mentioned, substantial forward trial have will talented amazing X and Raju last team. design also we this is a at trials more truly that Phase I In As VTXXXX January assembled dedicated add on individuals in be a details three X to sharing R&D we for an together look all several should to these Phase

conducting with for we're VTXXXX that we demonstrated oral trial in preclinical up of While X release gearing formulations we of dosing. have evaluations trials, planned X can Phase Phase been an TYKX that our approximate the convenient extended the duration coverage three of once-daily

early to position to the provide expect half in evaluate We to release an formulations a studies update XXXX. extended XXXX our bioavailability in and in relative be in human first of

is Phase trials, goal in formulation expect have X of could in ready for use VTXXXX Our release we begin which XXXX. to extended an

and score. remission of in if ongoing receptor high which patients upon improvement rapid using dose lymphocyte patients across SXPX measures. three-component a clinical that an the the approximately Mayo other VTXXXX, the The with and colitis. endpoint let's trial and clinical ulcerative greater potential reduction, our Etrasimod clinical dose designed SXP weeks may of is cohorts, and improve treatment moderate is VTXXXX This Zeposia modulators placebo is rates primary Now X three XX at modified low to modulator, ulcerative our We has to through XXX selective with arms trial correlate Phase induction other colitis higher of severe in achieved to believe efficacy VTXXXX in remission response attention which group. turn for to and enroll trial's

top estimate to for with data remain we been guiding trajectory X line enrollment complete Phase enrollment strong. on guidance. been be based we by that have the comfortable in current have and XXXX trends Recent And mid-XXXX. We

strong R&D well-tolerated large evidence engagement impact impact at a the Meanwhile, confirm been the with evidence X intend in compound. in CAPS broad the that potential data to second including look provide mechanism and quarter, in to of and study small additional data X as of exciting We such range Phase NLRPX the initiate on of inflammation as while high-sensitivity selection have safety let's released incremental our an addition in indications Next, target will be Phase demonstrated a clinical gain-of-function to a of indication proof down known on a resulting an in a patient fourth VTXXXXX, this potential diseases. update actively of an of trial target narrowing list target areas the This in during remains larger substantial rheumatologic We and opportunity. key engagement for earlier NLRPX C-reactive disease profile ultrarare January. event the to mentioned plan pharmacodynamic we inhibitor on commercial believe setting. NLRPX I that our effect focused from providing cardiovascular we disease markers peripheral safe in dermatologic, will in gene of a and disease indication and which We very protein. mutations VTXXXXX quarter.

the of fourth X is remain XXXX. our We quarter Phase inhibitor on a VTXXXXX. track penetrant NLRPX compound Our CNS initiate pipeline candidate in to trial first

pipeline more internally it we which so mover In you candidates. has NLRPX therapeutic very in We continue Alzheimer's portfolio of inhibitors progress We of inhibition. potential may believe now. of first our disease to a the proud efforts with also R&D the truly we during have to about team's and need and unmet drug disease high has and the penetrant our across candidate, concludes wholly diseases a great number Day among neuroinflammatory novel make that among I'm our and excited peripheral drug we owned forward with others. be sharing Parkinson's including to for January. This look CNS summary, believe in potent NLRPX are discovered update this utility

a financial Q&A, results. of like call to the we to for hand I'd move brief back discussion Before to Martin our

Marty Auster

I'll quarter briefly for were of quarter Thanks, million quarter XXXX, summarize pipeline in third of compared financial to XX.X expenses testing. third the advancement the results million the of later in reflecting now. clinical Bill. third XX.X of into R&D our stages our XXXX,

upwards alluded to trend in our year pipeline We G&A clinical over will build as three Phase expenses the continue VTXXXX and R&D that out as the the Bill trials for XXXX, earlier. expect of we X XX.X of to million balance launched the XXXX. our of third million, to compared quarter compared quarter the this XX.X quarter and to loss XXXX of was in in X.X for million to Approximately expenses net afternoon's cash third Cash, XXXX expense. the the and were believe net were third in compensation X.X $X million of in equivalents million, equivalents loss fund the quarter quarter non-cash of our September XXXX represents operations as and sufficient XXth CEO, into concludes to Dr. Mohan; the securities million session turn marketable and third Bill marketable CMO, we planned cash back operator securities This stock XXX.X and to are prepared current President remarks by where from rejoined I'll our this call the Sandborn. to be I'll call XXXX. commence Q&A and Operator? Dr. the the Raju and now continue

Operator

Thank you. question is now Yee [Operator first for The Michael Instructions] from questions. comes floor of Our Jefferies. open

Unidentified Analyst

pretty We're on for two X soon. This data for the top me. that Hi line for afternoon. good a is programs Phase be competitor will line. reporting questions Yee Michael their [indiscernible] Maybe TYKX aware

all, would second So interpret you're for could how understand view of data molecule? I on, And for your for how results first program, the SXP then, guiding of And and read-through it Ventyx? comment differentiation market you in the you on the maybe XXXX. comment Bill, should your

and want So in you. what do the could Thank comment you on your study expectations? you to see

Raju Mohan

you. thank Yes, Great.

SXPX So, let and the the take then question Bill me have I'll address first question.

we of differentiate a competitor shown we've and So in differentiation from Deucravacitinib. the molecular how on basis with compounds terms

how TYKX So translates for fold pathway. selectivity extremely alisteric we've for into selectivity selective X,XXX high domain. more this shown shown of We've the TYKX

XX all So hit alpha. pathways robustly, interferon XX, we and

interaction no have pathways. with JAKX We

no -- IL-X with of We and interferon IL-XX, gamma. IL-X, have interaction IL-XX, innovation no

Deucravacitinib. So the with differentiation we've molecular shown

hematological and differentiation shown coverage, Bill, target IC-XX More dissemination X terms of clinical in in what and seen well actually safety, to Phase X, the effects on IC-XX importantly, has terms well. head-to-head meaningful which compared other in is dermatological effects in data well across of the competitor significant the effects Phase we've and as as of during with Deucrava key the achieve trials been terms as of as coverage as compound

what IC-XX So coverage, target importantly we profile the but differentiation, and dose to is basis able compound data our and basis have IC-XX being for shown we've the a Deucravacitinib without ability the XX again, more you escalate, Sotyktu just on believe clinical that impact with that to competitor any cover for to against XX a meaningful of we hours remember, on and more publicly importantly molecular demonstrated, significant on VTX-XXX. mentioned, target given profile for available,

Now, dose how respect thus this data, in terms shown the efficacy a with versus the and ourselves to what Bill terms in safety and of the well-tolerated the this these But which compound. how IC-XX in for what to what events of molecule, competitors shown, it MAD, is compared of safety hours we the all ability for have again and safety we've manifestations what have I up have can highest ourselves to cover to position head-to-head shown position XX all think, are target to the events seen, is what are few program, had Deucrava trials. very of mild that data depends or the data versus XX up we seen compounds, which is competitor to in that far, we competitive way

more any follow-up over it up hand follow that, question on think I Bill. to -- I'll otherwise, So question

Bill Sandborn

All right.

So this hours short with many long-acting half-life. with the with modulator, the ZEPOSIA. That to XX -- or days for for and drug, VTX-XXX, to about etrasimod regard a XX-hour our SXP ozanimod a is dominant compares half-life metabolite relatively

primary first out like so with a of we is dose of typical. drug and titration weeks reduction the secondary things is a quickly. And then X. improvement, with The effects endpoint and So class the to see target endpoints carefully some that endoscopic the worked of the this remission Phase the in our full act include rate XX active period half-life address very key dosing two pretty allows you The short doses. heart dose one-week to trial that design

approved If There's multiple you and or SXP to at ponesimod look in arena. other the and Siponimod are ZYPOSIA. Gilenya PONVORY modulators, four or addition in or sclerosis there MAYZENT, fingolimod ozanimod

ZYPOSIA XX%, to contrast, By in multiple with up Phase range sort you ZYPOSIA Phase besides baseline. reductions reduction drugs, you to the to lymphocyte a saw sclerosis the and with X three have of XX%, other trials. reduction in XX% see are and XX% X etrasimod XX% The the from dosed XX% setting in in high XXs about

in you are lower get there considerably that greater really you sclerosis it's that And So lymphocyte multiple reduction. greater up to hints of that, see reduction lymphocyte as degrees efficacy.

observed to trials efficacy that reduction higher top clinical up that our over that's the So have in or believe, trial the is yet really to been of lymphocyte ZYPOSIA multiple we incremental experience, colitis. And could on which not based designed dose tested sclerosis both that the ulcerative range in has efficacy etrasimod. with and be been lead

Raju Mohan

Operator?

Operator

Yes, from you. from Thank our We'll question sir. Piper Sandler. next take Yasmeen Rahimi

Swapnil Malekar

for on is Yas. Thank Swapnil this taking for Hey, our questions. your

more color the psoriasis little in can the in doses for remaining And bit for the is, the are second studies of difference of X is what on Crohn's like, a some study? you thinking you about that to quarter? this Phase two order versus steps then are in initiate how us. provide the Just part One are

Raju Mohan

Yes.

So let address of me why Bill take Bill, these. have you don't those. both

Bill Sandborn

Yes.

at doses products of we of the I prepared top for -- will exposures think, for we target the tolerability. a particularly has adverse doses of drugs would our from IC-XX dermatologic dosing, very earlier with think day. that majority of coverage the had from been allow context that, other remarks range the that, been is is with look all for or much what the achieved and that that competitor of that across other in have event we the in cover the end And achieved off-target the really competitor different that, product that

For of Crohn's psoriasis. -- true sort actually we think it's equally disease, but for of

for antibodies, what higher you ICXX there's where You are hours. what and and would delta with XX the with those monoclonal have considerably And see see between outcome that coverage with anti-IL-XX for TYKX be a approved XXX can XX PASI-XX rates measures with that inhibitor psoriasis you antibodies. IL-XX we believe and

difference in also we see that's Crohn's will disease. psoriasis. give target it's coverage in what efficacy So in that But think to makes it that efficacy possible differentiated

So that to day level. IL-XX. will we Crohn's the of dose think all coverage or exposures have range Crohn's to most that robust it's ICXX the essential in to efficacy in and up our encompass for trial see disease

Raju Mohan

we've publicly we remains Yeah. to November. will year. what three two all done, Swapnil be in Phase, of this stated It's start terms

Swapnil Malekar

Okay.

Raju Mohan

the planning trials prep, three a tuned. three on into we're in It's months, track two but as work is of trials initiate goes just everything that right? all all than the less lot work to Stay and

Swapnil Malekar

you. Thank Okay.

Operator

Thank Our question you. next from [Operator Capital. Instructions] of LifeSci Slutsky comes Sam

Sam Slutsky

thanks is, Hi. questions proof my just point Thanks for right Deucravacitinib on be of route? And Got a there for you the that given when taking XXX. and to end, the And curious there's go my from for might few at question. first if about lupus update. so concept with expand indication how time to that then thinking you're this development that want

Raju Mohan

let Bill thanks Again, a in this. lot obviously some give And we'll for since And let came you lot me Day, about obviously out Deucravacitinib have our R&D more color we've thoughts. on Yeah. EULAR, this, have the about but Sam. this our address talk data me now, Bill, a at but talked

Bill Sandborn

Yeah.

saw is robust we data of that the think, lupus. EULAR in at Deucravacitinib evidence I efficacy presented

that reason greater other ICXX TYKX coverage there's would or target in reads who inhibitors Phase and the Deucravacitinib every to that ICXX have through levels. similar interferon-alpha so to believe with And X data

that coverage not. we lupus. would program the Deucravacitinib exceeds the options demonstrated and a meets that coverage lupus have trigger considering still will whether in We're or efficacy certainly in about we with So

that through But believe a indicate translational seeing about So Deucravacitinib the that. all reads our decision strongly efficacy the made to compound. we we're that medicine that we data with haven't

Sam Slutsky

Got it.

Okay.

there's from interesting they compared alone. recently remission rates a higher a Janssen where inhibitor the combined TNF saw for therapy inhibitor IL-XX have I Next either with one and data UC to is, some just an

to I point potential approach? makes given future guess the And what some tip or I'm So of to at your overall? on thinking -- combo then, a curious approaches some about sense the for it combination pipeline in combination you're SXPX how kind other do

Raju Mohan

I will think at bowel the is company in interesting Let of autoimmune and high-level, in colitis combination a role play the me That ulcerative with just combination think and really target future our think therapy with It data say we dose that and Janssen of I thinks VTXXXX plan the close very anti-TNF to doubled very therapy anti-IL-XX target. other we a potentially an disease that the is inflammatory we antibody anti-IL-XX the for coverage essentially the and interesting. way higher that have diseases. rates, remission end very to at

And need imagine the VTXXXX than posing so something the efficacy you with to sort dose were could what We more which and straightforward first out with is clinical TNF response you even trials. safety the blocker. simple and mix and to

that's and potentials focus our for monotherapy right as So the now, future. but the there

think hand I TYKX be any benefit thought interesting one what to around diligence on and is anticipate a lot modulator you SXP an mixing with inhibitor on would of require other. risk a the and it the

it's of focus So and plan. current come think great through in but question the to come, not it's we to our a years months the something will development

Sam Slutsky

it. Got

me. for Okay. last And just one

VTXXXX more on historically of to-date have new just formulation clinic, animal QDX, it translatability anything say data that? and kind the you be in of will the the able the to of realize I on you're Just but

Raju Mohan

Yeah.

build from we we a test our of beauty approach setting and the in formulations So is ER get-go. that, the human right protypes have

we'll ICXX model dose right? product target a hours. unmatched which validate is profile. human XX and we rapid ER the QD a this coverage really in TPP methods so profile the out a exposure coverage get of to to it target is data, PK have lay the a we build And then into prototype target the study so dosing optimizing which part to have and for this take with XX plan sort read number and we of QD where then, And iterations a for we to see tablet we And from of human test then once which and the clear profile, is achieve its the first

camp way And Bill we as show in to So our wrap that all share of hope the peak and optimizing to to the up the really first year. base QD from on a said, tablet. that half data happy and the target we'll

track, all all So, good, tuned. on stay

Sam Slutsky

it. Got

Okay, thank s.

Operator

Wainwright. our take We'll Bodnar next from you. of Emily question H.C. Thank

Emily Bodnar

taking question, two Hi. my for Thanks me. for

have colitis First, expect Crohn's you're of for other dermatitis? VTXXXX you'd that Phase do you for or the XXXX any looking do planning studies indications initiate is anticipate should be one that results. initiate any like data Thanks. studies the you in that besides XXX, either from of disease earliest to to X atopic And for ulcerative we for kind or

Raju Mohan

Yes.

will on So, first is three but start psoriasis. kick trial to out we severe our year in X psoriasis Phase moderate to the All to from this our off data read XXXX. in expect data trial plaque so

for severe see you with in So Phase XXXX. moderate XXX X patients to X the trial in Phase will data

you for we about consider. indications On the why that question, XXX might second Bill address that just don't other

Bill Sandborn

Crohn's trial that atopic that eosinophilic field trial products so Other indications in are and evaluated There's have esophagitis those include being in are dermatitis in all disease. possibilities. that Yes. a a

been play in these half this for we're indications mind. and certainly we've possibilities landscape think discussing our I the we other but little the some the a do are all We're in interesting see moment potential reasons of out. watching hour the other at busy

Emily Bodnar

you. Thank it. Got

Operator

Thompson Thank you. from next Instructions] Stifel. [Operator take We'll our question Alex of

Alex Thompson

a the better placebo for inhibition? follow-up I this hypothesis around confidence again have about do showed issues Phase weeks upcoming no in in succeed a Thanks better XX past And deucra NIMBUS that at wonder exposure can there's in XX XX%. at from efficacy much than to I taking in for I if I for TYKX on X adjustment safety XX question. the thanks trial if we NIMBUS. guess Hey assuming guess getting my data how they rates don't wanted they

Raju Mohan

have So, coverage. we are the best-in-class positioned to

the have the on higher had and XX-milligram We limited for dose to is coverage about nine for the data XX for trial X Phase dose. deucra in best-in-class the they ICXX hours coverage but data XX is ICXX and there at particular for coverage there where six-milligram from hours for

So, is as meaningful in there can out coverage. incremental there data differences XX passing you even get XX that suggest and passing you get higher

ICXX for And exist efficacy oral for TYKXs, biologic-like so while get right to have we now doesn't efficacy enough biologic-like precedence biologics coverage. from need you

right? and psoriatic obviously see wait for and on of not coverage across arthritis so as like, to psoriasis And add in efficacy also there what there's but just NIMBUS's from available a we'll anything Bill dose to that. want data travel that but deucrava look from response well. data set biologics the you So, terms clearly out

Bill Sandborn

Yes.

to Just reframe what slightly. you said

deucravacitinib BID once milligrams then various you a we've day milligrams six and XX day ones seen about adverse six as skin you having not once as ICXX three had between XX% to but day If ones nine in day. events. hours and by six the BID with six from going BID, think the went in the of And or X up milligrams with you any a milligrams as at difference or BID And coverage in three XX Phase patients XX said or is BID coverage XX% up and doses those maybe dose improve Raju that deucravacitinib stepping trials and XX XX%, all hours a to of much you eight then finding as ICXX hit recall a to

manifestations. by skin locked event the So adverse off-target that product really is the in in

of really finding because with interesting doses to the whole by exposure So, window. is yes, deucravacitinib, leading therapeutic but range limited an not there's range experiment dose are the that it's the

doses competitor dose the you hasn't as done. doses resulting XX and real not XXX different and the addressed. IL-XX/XX really to most response for you are coverage the what of coverage and the if are the responses maximum So, there's then out was data want to reads exposures of and yourself been response day ICXX PASIXX of and exposure question the getting whether ask and whether other see ICXX And

Alex Thompson

Okay, the thank Thanks for you. it. I color. appreciate

Bill Sandborn

Thanks Alex.

Operator

We'll you. question from our take of Jones Jeff Oppenheimer. Thank next

Jeff Jones

Thanks taking guys, my appreciate you and question. I

talked complex that SXP about dose the front Pfizer call. And titration. earnings context no a talked bit on little their about I On in more they being etrasimod guess

titration your as interested ongoing the population in JAK you're bio-naïve, the dose and you in well on your population use So as not Thank they for adoption versus Phase and the in population naïve the X? thoughts using studied being

Raju Mohan

Yes.

Let me expert have address it. SXPX the

Bill Sandborn

overstatement regimen Well, It's facts. defining a complex titration of push dose out and that as I every a deal. of have think big pills not the is an you It's pack blister you blister a the day.

I So limitation. is that think don't that important an

and advanced failure a biologic or advanced In terms naïve mixture therapy to of patient there was patients. populations, etrasimod recruited patients with therapy moderate severe ulcerative and colitis of

naïve it was something coming running still And on As like countries is split at our to XX-XX recall, different times. I trial a of failure. different

recruited will similar So to but failure final be the a class. drugs the fully the are you advanced naïve patients recruiting in mixture of until what mix know don't trial and is other therapy we

Jeff Jones

Okay. you. Thank

Bill Sandborn

Thanks, Jeff.

Operator

our Thank Tiago next We'll question take Credit Suisse. from you. of Fauth

Unidentified Analyst

receptors for John more its Thanks. the if Tiago. a or receptor Thanks What for SXP of our can about approach? avoiding you Hi VTX-XXX, any on X taking implications trade-offs terms selective of and for having efficacy just guys. of X potential for X. selectivity specifically question. It's safety through the in the On talk significance are

Raju Mohan

question. great Yes

its of SXPX lymphocyte let's for drugs of receptor of the ourselves or the efficacy, to for effectively SXPX mediates plethora just efficacy. and and really a trials It's class class, biology as SXPX SXPX sequestration. it drives that of data limit there's So, how data not MS biology modulation that across primarily SXPX through multiple

drugs of thought be really eventually the see over these MS. PX was So SXPX, even are selective is you a selective SXPX, consequence most into to a class though some extent consequence expressed CNS as they're SXPX, highly a in us. crossed that and for primarily a compounds to not to for

so compound CNS-penetrant non really inconsequential that a through is SXPX. you, driven remind me PX driving let in efficacy drug is activity Our

SXPX was to point we've sorry, update particular class so reference one dendritic I compound, etrasimod of SXPX in on its UC or with from IBD to think not again or of mechanism. cell Now and involved seen role all with drugs. primarily the in real view, an on And first of biology But there's just SXPX SXPX a our as -- is relevance particular. no in trafficking,

So drug, a again crossover. highly selective having non-relevant non-selective not is SXPX no

etrasimod being a it highly unlike doesn't hit consequences only again, selective positive to and selective for a So compound there's even drug. and SXPX,

Unidentified Analyst

it. much. you Thank so Got

Raju Mohan

welcome. You're

Operator

Thank remarks. turn Dr. would call you. to I Raju for like closing to some now Mohan back the

Raju Mohan

Well you really to all. accomplishments team NLRPX Yes. XXX in here. portfolio. attributes We're to Thanks pleased to for present quarter our of our thank highlight XXX, this the

And welcome out details R&D I'd to more date New on like in Day York, marked all you January sending to that XX, our so term. event the the in and be near really we'll

to forward you questions look there seeing all I'll So answering and in person.

So, you again. thank all,

Operator

your XXXX wonderful and at call. Biosciences this disconnect have This today's concludes third day. quarter line earnings time, conference a Ventyx Please

Ventyx Biosciences (VTYX) 6 Nov 222022 Q3 Earnings call transcript